56 Followers on Owler
Hansa Biopharma is a biopharmaceutical company that develops and markets immunomodulatory enzymes for the treatment of autoimmune diseases...
Read moreHansa Biopharma is a biopharmaceutical company that develops and markets immunomodulatory enzymes for the treatment of autoimmune diseases...
Read more
News
Mar 18, 2023
Owler
Hansa Biopharma AB: Hansa Biopharma's employee count changed from 145 in Sep 2022 to 150 in Dec 2022
Mar 03, 2023
Marketscreener
Hansa Biopharma: Hansa Biopharma AB Appoints Matthew Shaulis as Chief Commercial Officer and US President of Hansa Biopharma
Feb 04, 2023
Seeking Alpha
Hansa Biopharma: Hansa Biopharma AB (publ) (HNSBF) Q4 2022 Earnings Call Transcript
Feb 02, 2023
Markets Insider
Hansa Biopharma: Hansa Biopharma GAAP EPS of -SEK 3.19, revenue of SEK 31M
Feb 02, 2023
StreetInsider
Press Release: Hansa Biopharma : Hansa Biopharma Year-end report January-December 2022
Jan 30, 2023
Cision
Press Release: Hansa Biopharma : Hansa Biopharma announces planned departure of Chief Scientific Officer Christian Kjellman
Jan 18, 2023
Global Legal Chronicle
Hansa Biopharma: Hansa Biopharma's SEK 415.9 Million Directed Share Issue
Jan 03, 2023
Pharmabiz
Hansa Biopharma: Hansa Biopharma attains reimbursement in Czech Republic for its firstinclass treatment, Idefirix
Dec 09, 2022
Pharmabiz
Hansa Biopharma: AIFA grants full access and reimbursement for Hansa Biopharma's Idefirix as desensitization treatment for highly sensitized patients in kidney transplantation
Nov 28, 2022
centralcharts
Press Release: Hansa Biopharma : Hansa Biopharma announces positive topline data from the imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation
Looking for similar companies to Hansa Biopharma?
Hansa Biopharma Quarterly and Annual Revenue
Trailing 12-Months Trend (TTM)
Annual Revenue
$14.8M
Hansa Biopharma's revenue is the ranked 2nd among it's top 10 competitors. The top 10 competitors average 25M. Over the last three quarters, Hansa Biopharma's revenue has grown by 441.2%. Specifically, in Q1 2022's revenue was $32.3M; in Q2 2022, it was $2.6M; in Q3 2022, it was $6M.
Hansa Biopharma News
Hansa Biopharma Press Releases
Hansa Biopharma Headquarters
Hansa Biopharma Summary
ABOUT
Overview
Hansa Biopharma is a biopharmaceutical company that develops and markets immunomodulatory enzymes for the treatment of autoimmune diseases. Hansa Biopharma was founded in 2007. Hansa Biopharma's headquarters is located in Lund, Skåne län, SE 22007. H...CEO
Hansa Biopharma's President & CEO, Søren Tulstrup, currently has an approval rating of 90%. Hansa Biopharma's primary competitors are Akari Therapeutics, Curavac, Annexon and 2 more.Website
hansabiopharma.comCompetitors
View 5 Hansa Biopharma competitors here.Investments
Recent investment data cannot be found related to Hansa BiopharmaFrequently Asked Questions about Hansa Biopharma
When was Hansa Biopharma founded?
Hansa Biopharma was founded in 2007Who is Hansa Biopharma's CEO?
Hansa Biopharma's CEO is Søren TulstrupHow much revenue does Hansa Biopharma generate?
Hansa Biopharma generates $14.8M in revenueHow much funding does Hansa Biopharma have?
Hansa Biopharma has historically raised $186M in funding
Where is Hansa Biopharma's headquarters?
Hansa Biopharma's headquarters is in Lund Skåne län, SEHow many employees does Hansa Biopharma have?
Hansa Biopharma has 150 employeesWhat sector does Hansa Biopharma operate in?
Hansa Biopharma is in PharmaceuticalsWho are Hansa Biopharma's competitors?
Hansa Biopharma's top competitors are Akari Therapeutics, Curavac, Annexon